Answers are grounded in this paper and cite their sources.
Retrospective cohort study compares mortality and outcomes in septic patients treated with MB or HC, highlighting implications for treatment strategies.
Purpose Adjuncts targeting pathologic vasodilation in septic shock are of interest when standard strategies fail. Guidelines recommend norepinephrine, vasopressin, and epinephrine; neither methylene blue (MB) nor high-dose hydroxocobalamin (HC) are addressed with a recommendation. MB has signals for faster shock reversal and possible short-term mortality reduction, with low-certainty evidence. HC reduced vasopressor dose but has not shown outcome benefits, and evidence in sepsis remains sparse. Direct comparative data between MB and HC in sepsis are lacking. We compared clinical outcomes among septic patients treated with either MB or HC in a large EHR network. Methods Retrospective cohort study using the TriNetX U.S. network (65 health systems). Adults (≥18 y) hospitalized with sepsis, severe sepsis, or septic shock (1/1/2016-1/1/2025) were included. Exclusions: nitroprusside exposure, methemoglobinemia, or cardiogenic shock. Exposure groups comprised patients receiving only MB or only HC; patients receiving neither agent were excluded to avoid treatment-severity bias. Primary outcomes: all-cause mortality in two windows: 3-to-7-days post-therapy and 7-day mortality. Secondary outcomes: AKI, CRRT initiation, atrial fibrillation, ventricular tachycardia, ventilator/hospital-acquired pneumonia, stroke, vasoplegia requiring midodrine, and vasopressor use after 3 days. Propensity score matching (1:1) used 91 covariates across demographics, comorbidities, procedures, medications, and labs. Results After matching, 732 patients were analyzed (MB = 366; HC = 366). Mortality did not differ between MB and HC at 3-to-7 days (9.8% vs 12.6%, p = 0.241) or at 7 days (29.5% vs 35.0%, p = 0.114); Kaplan-Meier curves were concordant. AKI rates were similar (both windows p > 0.16). CRRT initiation was higher after HC at both time points (3-to-7 days: 10.5% vs 3.3%, p < 0.001; 7 days: 29.0% vs 16.9%, p < 0.001). Stroke was more frequent with HC in the 3-to-7-day window (3.0% vs 0.0%, p = 0.002) but not at 7 days. Ongoing vasopressor use beyond 72 h was higher with HC in the 3-to-7-day window (51.1% vs 39.1%, p = 0.001) but not at 7 days. Other secondary outcomes were similar. Conclusions In real-world septic shock, MB and HC showed no difference in early mortality, consistent with current evidence. MB was associated with lower CRRT initiation despite similarly coded AKI, suggesting potential non-renal indications for CRRT or residual confounding. Transient differences in stroke and prolonged vasopressor exposure favored MB early but attenuated by day 7. Given prior data supporting faster shock reversal with MB, our findings support MB as the more favorable adjunct. Causal inference is limited by observational design, residual confounding, exposure misclassification, and code-based outcome ascertainment.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: